Biotricity CEO letter cites record Q2 revenue of $1.81M (+143% YoY), sets 2022 goals

BIOTRICITY INC.

Record quarterly revenue of $1.81M for Q2 FY2022 ended Sep 30, 2021, up 143% YoY, tenth consecutive triple-digit growth quarter.
Recent uplisting to Nasdaq to attract larger investor pool and increase liquidity.
Introduced Biokit, a 3-device personal medical kit for integration into Biotricity ecosystem.
Product roadmap includes Bioflux, Biotres, Biocare Telemed, and Bioheart.
2022 goals: launch new cardiac monitoring solutions and software services to become turnkey cardiac health provider.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.